Prepuberal intranasal dopamine treatment in an animal model of ADHD ameliorates deficient spatial attention, working memory, amino acid transmitters and synaptic markers in prefrontal cortex, ventral and dorsal striatum

Amino Acids

Volumn 46, Issue 9, 2014, Pages 2105-2122

  Ruocco, L A ^a   Treno, C ^a   Gironi Carnevale, U A ^a   Arra, C ^b   Mattern, C ^c,h   Huston, J P ^d   De Souza Silva, M A ^d   Nikolaus, S ^e   Scorziello, A ^a   Nieddu, M ^f   Boatto, G ^f   Illiano, P ^g   Pagano, C ^g   Tino, A ^g   Sadile, A G ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b Ist Naz Tumorifond G Pascale   (Italy)

^c M et P Pharma AG   (Switzerland)

^d HEINRICH HEINE UNIVERSITY   (Germany)

^e UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^f UNIVERSITY OF SASSARI   (Italy)

^g CNR   (Italy)

^h NOVA SOUTHEASTERN UNIVERSITY   (United States)

Author keywords

ADHD; Attention; Dopamine transporter; Intranasal dopamine; L Aspartate; L Glutamate; NMDA receptor; Tyrosine hydroxylase; Working memory

Indexed keywords

AMINO ACID; ASPARTIC ACID; DOPAMINE; DOPAMINE TRANSPORTER; GLUTAMIC ACID; LEUCINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 1; TYROSINE 3 MONOOXYGENASE; DOPAMINE AGENTS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATTENTION; ATTENTION DEFICIT DISORDER; BASAL GANGLION; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC ACTIVITY; DORSAL STRIATUM; DOSE RESPONSE; DOWN REGULATION; DRUG DOSE COMPARISON; DRUG MECHANISM; EMOTIONALITY; MALE; MAZE TEST; MESENCEPHALON; NERVE CELL PLASTICITY; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; RAT; SUBSTANTIA NIGRA; VENTRAL TEGMENTUM; WORKING MEMORY; ADMINISTRATION, INTRANASAL; ANIMALS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; METABOLISM; PHYSIOPATHOLOGY; RATS; RATS, SPRAGUE-DAWLEY; SEXUAL MATURATION; VENTRAL STRIATUM;

ANIMALIA; PARKINSONIA; RATTUS; RODENTIA;

ADMINISTRATION, INTRANASAL; ANIMALS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; DISEASE MODELS, ANIMAL; DOPAMINE; DOPAMINE AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MALE; RATS; RATS, SPRAGUE-DAWLEY; SEXUAL MATURATION; VENTRAL STRIATUM;

EID: 84906323519     PISSN: 09394451     EISSN: 14382199     Source Type: Journal    
DOI: 10.1007/s00726-014-1753-8     Document Type: Article

References (63)

1. Aspide R, Gironi Carnevale UA, Sergeant JA, Sadile AG (1998) Nonselective attention and nitric oxide in putative animal models of Attention-Deficit Hyperactivity Disorder. Behav Brain Res 95:123-133 (Pubitemid 28400378)
2. Barbeito L, Girault JA, Godeheu G, Pittaluga A, Glowinski J, Cheramy A (1989) Activation of the bilateral corticostriatal glutamatergic projection by infusion of GABA into thalamic motor nuclei in the cat: an in vivo release study. Neuroscience 28:365-374 (Pubitemid 19053078)
3. Berke JD, Breck JT, Eichenbaum H (2009) Striatal versus hippocampal representations during win-stay maze performance. J Neurophysiol 101:1575-1587
4. Buddenberg TE, Topic B, Mahlberg ED, De Souza Silva MA, Huston JP, Mattern C (2008) Behavioral actions of intranasal application of dopamine: effects on forced swimming, elevated plus-maze and open field parameters. Neuropsychobiology 57:70-79 (Pubitemid 351859337)
5. Capowski JJ (1989) Computer techniques in neuroanatomy. Plenum, New York
6. Chemuturi NV, Haraldsson JE, Prisinzano T, Donovan M (2006) Role of dopamine transporter (DAT) in dopamine transport across the nasal mucosa. Life Sci 79:1391-1398 (Pubitemid 44215932)
7. Chen N, Reith ME (2000) Structure and function of the dopamine transporter. Eur J Pharmacol 405:329-339
8. Clow DW, Jhamandas K (1989) Characterization of L-glutamate action on the release of endogenous dopamine from the rat caudate-putamen. J Pharmacol Exp Ther 248:722-728 (Pubitemid 19090245)
9. Dahlin M, Bergman U, Jansson B, Bjork E, Brittebo E (2000) Transfer of dopamine in the olfactory pathway following nasal administration in mice. Pharm Res 17:737-742
10. Dahlin M, Jansson B, Bjork E (2001) Levels of dopamine in blood and brain following nasal administration to rats. Eur J Pharm Sci 14:75-80 (Pubitemid 32655418)
11. D'Aniello A (2007) D-Aspartic acid: an endogenous amino acid with an important neuroendocrine role. Brain Res Rev 53:215-234
12. De Souza Silva MA, Topic B, Huston JP, Mattern C (2008) Intranasal dopamine application increases dopaminergic activity in the neostriatum and nucleus accumbens and enhances motor activity in the open field. Synapse 62:176-184 (Pubitemid 351186398)
13. Del Campo N, Chamberlain SR, Sahakian BJ, Robbins TW (2011) The roles of dopamine and noradrenaline in the pathophysiology and treatment of attention-deficit/hyperactivity disorder. Biol Psychiatry 69:e145-e157
14. Dorval KM, Wigg KG, Crosbie J, Tannock R, Kennedy JL, Ickowicz A, Pathare T, Malone M, Schachar R, Barr CL (2007) Association of the glutamate receptor subunit gene GRIN2B with attention-deficit/hyperactivity disorder. Genes Brain Behav 6:444-452 (Pubitemid 47024958)
15. Dougherty DD, Bonab AA, Spencer TJ, Rauch SL, Madras BK, Fischman AJ (1999) Dopamine transporter density in patients with attention deficit hyperactivity disorder. Lancet 354:2132-2133 (Pubitemid 30008900)
16. Dresel S, Krause J, Krause KH, LaFougere C, Brinkbäumer K, Kung HF, Hahn K, Tatsch K (2000) Attention deficit hyperactivity disorder: binding of [99mTc]TRODAT-1 to the dopamine transporter before and after methylphenidate treatment. Eur J Nucl Med 27:1518-1524
17. Errico F, Rossi S, Napolitano F, Catuogno V, Topo E, Fisone G, D'Aniello A, Centonze D, Usiello A (2008) D-aspartate prevents corticostriatal long-term depression and attenuates schizophrenia-like symptoms induced by amphetamine and MK-801. J Neurosci 28:10404-10414
18. Flint RS, Murphy JM, Calkins PM, McBride WJ (1985) Monoamine, amino acid and cholinergic interactions in slices of rat cerebral cortex. Brain Res Bull 15:197-202 (Pubitemid 15017260)
19. Fumagalli F, Frasca A, Racagni G, Riva MA (2008) Dynamic regulation of glutamatergic postsynaptic activity in rat prefrontal cortex by repeated administration of antipsychotic drugs. Mol Pharmacol 73:1484-1490 (Pubitemid 351574838)
20. Graff CL, Pollack GM (2005) Nasal drug administration: potential for targeted central nervous system delivery. J Pharm Sci 94:1187-1195 (Pubitemid 40904183)
21. Hoerst M, Weber-Fahr W, Tunc-Skarka N, Ruf M, Bohus M, Schmahl C, Ende G (2010) Correlation of glutamate levels in the anterior cingulate cortex with self-reported impulsivity in patients with borderline personality disorder and healthy controls. Arch Gen Psychiatry 67:946-954
22. Hosenbocus S, Chahal R (2013a) Amantadine: a review of use in child and adolescent psychiatry. J Can Acad Child Adolesc Psychiatry 22:55-60
23. Hosenbocus S, Chahal R (2013b) Memantine: a review of possible uses in child and adolescent psychiatry. J Can Acad Child Adolesc Psychiatry 22:166-171
24. Illum L (2007) Nanoparticulate systems for nasal delivery of drugs: a real improvement over simple systems? J Pharm Sci 96:473-483
25. Jucaite A, Fernell E, Halldin C, Forssberg H, Farde L (2005) Reduced midbrain dopamine transporter binding in male adolescents with attention-deficit/hyperactivity disorder: association between striatal dopamine markers and motor hyperactivity. Biol Psychiatry 57:229-238 (Pubitemid 40187366)
26. Krause J (2008) SPECT and PET of the dopamine transporter in attention-deficit/hyperactivity disorder. Expert Rev Neurother 8:611-625
27. Krause KH, Dresel SH, Krause J, Kung HF, Tatsch K (2000) Increased striatal dopamine transporter in adult patients with attention deficit hyperactivity disorder: effects of methylphenidate as measured by single photon emission computed tomography. Neurosci Lett 285:107-110 (Pubitemid 30227631)
28. La Fougere C, Krause J, Krause KH, Josef Gildehaus F, Hacker M, Koch W, Hahn K, Tatsch K, Dresel S (2006) Value of 99mTc-TRODAT-1 SPECT to predict clinical response to methylphenidate treatment in adults with attention deficit hyperactivity disorder. Nucl Med Commun 27:733-737 (Pubitemid 44213031)
29. Langer SZ (1997) 25 years since the discovery of presynaptic receptors: present knowledge and future perspectives. Trends Pharmacol Sci 18:95-99
30. Larisch R, Sitte W, Antke C, Nikolaus S, Franz M, Tress W, Müller HW (2006) Striatal dopamine transporter density in drug naive patients with attention-deficit/hyperactivity disorder. Nucl Med Commun 27:267-270 (Pubitemid 44391815)
31. Lesch KP, Merker S, Reif A, Novak M (2013) Dances with black widow spiders: dysregulation of glutamate signalling enters centre stage in ADHD. Eur Neuropsychopharmacol 23:479-491
32. Nikolaus S, Antke C, Müller HW (2009) In vivo imaging of synaptic function in the central nervous system. II. Mental and affective disorders. Behav Brain Res 204:32-66
33. Nikolaus S, Beu M, Antke C, Müller HW (2010) Cortical GABA, striatal dopamine and midbrain serotonin as the key players in compulsive and anxiety disorders - results from in vivo imaging studies. Rev Neurosci 21:119-139
34. Nikolaus S, Hautzel H, Heinzel A, Müller HW (2012) Key players in major and bipolar depression - a retrospective analysis of in vivo imaging studies. Behav Brain Res 232:358-390
35. Nikolaus S, Hautzel H, Heinzel A, Müller HW (2014) Neurochemical dysfunction in treated and nontreated schizophrenia - a retrospective analysis of in vivo imaging studies. Rev Neurosci 25:25-96
36. Paxinos G, Watson C (2007) The rat brain in stereotaxic coordinates. Academic Press, London
37. Peris J, Dunwiddie TV (1985) Inhibitory neuromodulation of release of amino acid neurotransmitters. Alcohol Drug Res 6:253-264 (Pubitemid 16170485)
38. Pum ME, Schäble S, Harooni HE, Topic B, de Souza Silva MA, Li J-S, Mattern C, Huston JP (2009) Effects of intranasally applied dopamine on behavioral asymmetries in rats with unilateral 6-OHDA lesions of the nigro-striatal tract. Neuroscience 162(1):174-183
39. Purper-Ouakil D, Wohl M, Michel G, Mouren MC, Gorwood P (2004) Symptom variations in ADHD: importance of context, development and comorbidity. Encephale 30:533-539
40. Rodriguez FJ, Lluch M, Dot J, Blanco I, Rodriguez-Alvarez J (1997) Histamine modulation of glutamate release from hippocampal synaptosomes. Eur J Pharmacol 323:283-286 (Pubitemid 27152283)
41. Ruocco LA, de Souza Silva MA, Topic B, Mattern C, Huston JP, Sadile AG (2009a) Intranasal application of dopamine reduces activity and improves attention in Naples High Excitability rats that feature the mesocortical variant of ADHD. Eur Neuropsychopharmacol 19:693-701
42. Ruocco LA, Gironi Carnevale UA, Sica A, Arra C, Topo E, Di MA, D'Aniello A, Sadile AG (2009b) Elevated forebrain excitatory L-glutamate, L-aspartate and D-aspartate in the Naples highexcitability rats. Behav Brain Res 198:24-28
43. Ruocco LA, Sadile AG, Gironi Carnevale UA (2009c) Modeling the mesocortical mariant of ADHD: the Naples high excitability rats. In: Gordon SM, Mitchell AM (eds) Attention deficit hyperactivity disorder. Nova Science, New York, pp 85-106
44. Ruocco LA, Gironi Carnevale UA, Sica A, Arra C, Topo E, Di Maio A, Di Giovanni M, D' Aniello A, Sadile AG (2009d) Differential prepuberal handling modifies behaviour and excitatory amino acids in the forebrain of the naples high-excitability rats. Behav Brain Res 198:29-36
45. Rüsch N, Boeker M, Büchert M, Glauche V, Bohrmann C, Ebert D, Lieb K, Hennig J, Tebartz Van Elst L (2010) Neurochemical alterations in women with borderline personality disorder and comorbid attention-deficit hyperactivity disorder. World J Biol Psychiatry 11:372-381
46. Russell VA (2011) Overview of animal models of attention deficit hyperactivity disorder (ADHD). Curr Protoc Neurosci Chapter 9(Unit9):35
47. Sadile AG, Pellicano MP, Sagvolden T, Sergeant JA (1996) NMDA and non-NMDA sensitive [L-3H]glutamate receptor binding in the brain of the Naples high- and low-excitability rats: an autoradiographic study. Behav Brain Res 78(2):163-174 (Pubitemid 26252885)
48. Sagvolden T (2000) Behavioral Validation of the Spontaneously Hypertensive Rat (SHR) as an animal model of Attention-Deficit Hyperactivity Disorder (AD/HD). Neurosci Biobehav Rev 24:31-40
49. Sergeant JA, Geurts H, Huijbregts S, Scheres A, Oosterlaan J (2003) The top and the bottom of ADHD: a neuropsychological perspective. Neurosci Biobehav Rev 27:583-592 (Pubitemid 37414907)
50. Solanto MV (1998) Neuropsychopharmacological mechanisms of stimulant drug action in attention-deficit hyperactivity disorder: a review and integration. Behav Brain Res 94:127-152
51. Sonuga-Barke EJ (2003) The dual pathway model of AD/HD: an elaboration of neuro-developmental characteristics. Neurosci Biobehav Rev 27:593-604
52. Spencer TJ, Biederman J, Madras BK, Dougherty DD, Bonab AA, Livni E, Meltzer PC, Martin J, Rauch S, Fischman AJ (2007) Further evidence of dopamine transporter dysregulation in ADHD: a controlled PET imaging study using altropane. Biol Psychiatry 62:1059-1061 (Pubitemid 47562362)
53. Steinhoff KW (2008) Special issues in the diagnosis and treatment of ADHD in adolescents. Postgrad Med 120:60-68
54. Tayebati SK, Nwankwo IE, Amenta F (2013) Intranasal drug delivery to the central nervous system: present status and future outlook. Curr Pharm Des 19:510-526
55. Thorne RG, Frey WH (2001) Delivery of neurotrophic factors to the central nervous system: pharmacokinetic considerations. Clin Pharmacokinet 40:907-946 (Pubitemid 34066688)
56. Tolleson C, Claassen D (2012) The function of tyrosine hydroxylase in the normal and Parkinsonian brain. CNS Neurol Disord Drug Targets 11:381-386
57. Van Dyck CH, Quinlan DM, Cretella LM, Staley JK, Malison RT, Baldwin RM, Seibyl JP, Innis RB (2002) Unaltered dopamine transporter availability in adult attention deficit hyperactivity disorder. Am J Psychiatry 159:309-312 (Pubitemid 34126913)
58. Viggianao D, Sadile AG (2000) Hypertrophic A10 dopamine neurones in a rat model of attention-deficit hyperactivity disorder (ADHD). Neuroreport 11:3677-3680
59. Viggiano D, Vallone D, Welzl H, Sadile AG (2002a) The Naples high- and low-excitability rats: selective breeding, behavioral profile, morphometry, and molecular biology of the mesocortical dopamine system. Behav Genet 32:315-333 (Pubitemid 35192993)
60. Viggiano D, Grammatikopoulos G, Sadile AG (2002b) A morphometric evidence for a hyperfunctioning mesolimbic system in an animal model of ADHD. Behav Brain Res 130:181-189 (Pubitemid 34195334)
61. Viggiano D, Vallone D, Ruocco LA, Sadile AG (2003) Behavioural, pharmacological, morpho-functional molecular studies reveal a hyperfunctioning mesocortical dopamine system in an animal model of attention deficit and hyperactivity disorder. Neurosci Biobehav Rev 27:683-689 (Pubitemid 37414916)
62. Volkow ND, Wang GJ, Fowler JS, Ding YS (2005) Imaging the effects of methylphenidate on brain dopamine: new model on its therapeutic actions for attention-deficit hyperactivity disorder. Biol Psychiatry 57:1410-1415 (Pubitemid 40798562)
63. Yamamoto BK, Davy S (1992) Dopaminergic modulation of glutamate release in striatum as measured by microdialysis. J Neurochem 58:1736-1742